Document is current
Any future updates will be listed below
-
Authors
Ásgrímsdóttir, Emilía Sif https://orcid.org/0000-0003-1509-6853
Bassini, Luca Fusar https://orcid.org/0009-0005-8256-8074
Sun, Ting https://orcid.org/0000-0002-7104-7215
Puigsasllosas Pastor, Clàudia https://orcid.org/0009-0007-6498-5223
di Val Cervo, Pia Rivetti https://orcid.org/0000-0001-5999-1230
Gyllborg, Daniel
Lee, Kawai
Grigsby, Christopher L. https://orcid.org/0000-0002-0105-3847
Jude, Baptiste https://orcid.org/0000-0002-5506-2482
Abaurre, Carmen https://orcid.org/0000-0002-7800-2829
Islam, Saiful
Lönnerberg, Peter
Villaescusa, Carlos
Saltó, Carmen
Barker, Roger A. https://orcid.org/0000-0001-8843-7730
Linnarsson, Sten https://orcid.org/0000-0002-3491-3444
Castelo-Branco, Goncalo https://orcid.org/0000-0003-2247-9393
La Manno, Gioele https://orcid.org/0000-0003-1428-8757
Toledo, Enrique M. https://orcid.org/0000-0002-1460-4708
Arenas, Ernest https://orcid.org/0000-0003-0197-6577
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 5 January 2026
First Online: 16 February 2026
Competing interests
: E.A. is the founder, shareholder and scientific advisor of Cholestenix. E.M.T. and C.V. are Novo Nordisk employees. D.G. is a 10x Genomics employee. S.I. is Freenome employee. The other authors declare no competing interests.
